Anti-CD19 CAR T cell therapy, while transformative for cancer treatment, carries inherent risks when applied to autoimmune diseases, where the safety profile may differ due to the absence of tumor masses or malignant cell infiltration typically seen in cancers. Here, CD19 is linked to autoimmune disease.